TargetMol

AC-4

Product Code:
 
TAR-T26540
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26540-5mg5mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26540-50mg50mg£1,982.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26540-100mg100mg£2,560.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AC-4 is a blocker of photoswitchable TRPV1 channel.
CAS:
1459809-09-6
Formula:
C26H25F3N4O2S
Molecular Weight:
514.57
Purity:
0.98
SMILES:
Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(cc1)N=Nc1ccc(cc1)C(F)(F)F

References

1. Brunin G, Sajjad A, Kim EJ, Montes de Oca I, Weikert MP, Wang L, Koch DD, Al-Mohtaseb Z. Secondary intraocular lens implantation: Complication rates, visual acuity, and refractive outcomes. J Cataract Refract Surg. 2017 Mar;43(3):369-376. doi: 10.1016/j.jcrs.2016.12.024. PubMed PMID: 28410720. 2. Lin LD, Li XX, Qi YJ, Ma X, Zheng ST. Cluster Organic Frameworks Constructed from Heterometallic Supertetrahedral Cluster Secondary Building Units. Inorg Chem. 2017 Apr 17;56(8):4636-4643. doi: 10.1021/acs.inorgchem.7b00267. Epub 2017 Mar 27. PubMed PMID: 28345883. 3. Wei X, Nbelayim PS, Kawamura G, Muto H, Matsuda A. Ag nanoparticle-filled TiO(2) nanotube arrays prepared by anodization and electrophoretic deposition for dye-sensitized solar cells. Nanotechnology. 2017 Mar 1;28(13):135207. doi: 10.1088/1361-6528/aa5f11. Epub 2017 Mar 3. PubMed PMID: 28256452. 4. Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, Hudis CA, Dang C. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist. 2017 Feb;22(2):139-143. doi: 10.1634/theoncologist.2016-0268. Epub 2017 Feb 6. PubMed PMID: 28167568; PubMed Central PMCID: PMC5330708.